摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5,6,7,8-tetrahydro-(1,2,4)triazolo(4,3-a)-pyrazine hydrochloride

中文名称
——
中文别名
——
英文名称
5,6,7,8-tetrahydro-(1,2,4)triazolo(4,3-a)-pyrazine hydrochloride
英文别名
5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride;5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine hydrochloride;5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine;hydrochloride
5,6,7,8-tetrahydro-(1,2,4)triazolo(4,3-a)-pyrazine hydrochloride化学式
CAS
——
化学式
C5H8N4*ClH
mdl
——
分子量
160.606
InChiKey
NKEHUOIDQUKFDV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    42.7
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    5,6,7,8-tetrahydro-(1,2,4)triazolo(4,3-a)-pyrazine hydrochloride盐酸1-羟基苯并三唑1-(3-二甲基氨基丙基)-3-乙基碳二亚胺N,N-二异丙基乙胺 作用下, 以 甲醇N,N-二甲基甲酰胺 为溶剂, 反应 1.0h, 生成 7-[(3R)-3-amino-4-(3,4-difluorophenyl)butanoyl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine dihydrochloride
    参考文献:
    名称:
    (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
    摘要:
    A novel series of beta-amino amides incorporating fused heterocycles, i.e., triazolopiperazines, were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (1) is a potent, orally active DPP-IV inhibitor (IC(50) = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclinical species, and in vivo efficacy in animal models. MK-0431, the phosphate salt of compound 1, was selected for development as a potential new treatment for type 2 diabetes.
    DOI:
    10.1021/jm0493156
  • 作为产物:
    描述:
    8-氯三唑并[4,3-a]吡嗪platinum(IV) oxide palladium on activated charcoal 、 氢气 作用下, 以 甲醇 为溶剂, 反应 14.0h, 生成 5,6,7,8-tetrahydro-(1,2,4)triazolo(4,3-a)-pyrazine hydrochloride
    参考文献:
    名称:
    (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
    摘要:
    A novel series of beta-amino amides incorporating fused heterocycles, i.e., triazolopiperazines, were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (1) is a potent, orally active DPP-IV inhibitor (IC(50) = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclinical species, and in vivo efficacy in animal models. MK-0431, the phosphate salt of compound 1, was selected for development as a potential new treatment for type 2 diabetes.
    DOI:
    10.1021/jm0493156
点击查看最新优质反应信息

文献信息

  • PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF
    申请人:Tang Peng Cho
    公开号:US20130131068A1
    公开(公告)日:2013-05-23
    A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof are described.
    一种以化学式(I)表示的邻苯二氮酮酮衍生物,其制备方法,含有该衍生物的药物组合物,其作为聚(ADP-核糖)聚合酶(PARP)抑制剂的用途,以及其癌症治疗方法被描述。
  • [EN] 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER<br/>[FR] COMPOSÉS DE 2,4'-BIPYRIDINYLE COMME INHIBITEURS DE LA PROTÉINE KINASE D UTILES POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE ET DU CANCER
    申请人:NOVARTIS AG
    公开号:WO2009150230A1
    公开(公告)日:2009-12-17
    The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.
    本发明提供了式I的新型有机化合物:其使用方法和药物组合物。
  • Indole compound
    申请人:Yasuma Tsuneo
    公开号:US20080096877A1
    公开(公告)日:2008-04-24
    The purpose of the present invention is to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein R 1 is a hydrogen atom or a halogen atom; R 2 is a group represented by wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.
    本发明的目的是提供一种作为药物剂如用于预防或治疗糖尿病、肥胖等的葡萄糖激酶激活剂有用的葡萄糖激酶激活剂。 本发明提供了一种包含由公式(I)表示的化合物的葡萄糖激酶激活剂: 其中 R1 是氢原子或卤素原子; R2 是由表示的组 其中每个符号在说明书中定义,或其盐或前药。
  • Substituted Sulfonamide Compounds
    申请人:Merla Beatrix
    公开号:US20090186899A1
    公开(公告)日:2009-07-23
    Substituted sulfonamide compounds corresponding to the formula I wherein m, n, p, Q, R 1 , R 2 , R 3 , R 4 , X, Y and Z have the respective meanings defined herein, pharmaceutical compositions containing such compounds, a process for their preparation, and the use of such compounds for the treatment and/or inhibition of pain and other conditions mediated by bradykinin receptor 1 (B1R) and/or bradykinin receptor 2 (B2R).
    对应于公式I的磺胺基替代化合物,其中m、n、p、Q、R1、R2、R3、R4、X、Y和Z具有在此定义的各自含义,包含这种化合物的药物组合物,其制备方法,以及利用这种化合物治疗和/或抑制由激肽激酶受体1(B1R)和/或激肽激酶受体2(B2R)介导的疼痛和其他病症。
  • [EN] SUBSTITUTED SULFONAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE SULFONAMIDES SUBSTITUÉS
    申请人:GRUENENTHAL GMBH
    公开号:WO2009090055A1
    公开(公告)日:2009-07-23
    The invention relates to substituted sulfonamide derivatives of the general formula (I'); processes for their preparation, medicaments containing these compounds, and the use of substituted sulfonamide derivatives for the preparation of medicaments
    该发明涉及一般式(I')的取代磺胺基衍生物,其制备方法,含有这些化合物的药物,以及用于制备药物的取代磺胺基衍生物的用途
查看更多

同类化合物

西他列汀杂质10 [1,2,4]噻唑并[1,5-a]吡嗪-2-胺 N-(1,1-二甲基乙基)-5,6,7,8-四氢-1,2,4-噻唑并[4,3-a]吡嗪-3-羧胺 8-苯基-3-(三氟甲基)-5,6,7,8-四氢-[1,2,4]三唑并[4,3-a]吡嗪盐酸盐 8-肼基-[1,2,4]三唑并[1,5-a]吡嗪 8-甲基-3-(三氟甲基)-5,6,7,8-四氢[1,2,4]三唑并[4,3-a]吡嗪盐酸盐(1:1) 8-甲基-3-(三氟甲基)-5,6,7,8-四氢[1,2,4]三唑并[4,3-a]吡嗪 8-氯[1,2,4]噻唑并[1,5-a]吡嗪 7-Boc-5,6,7,8-四氢-1,2,4-三唑并[4,5-a]吡嗪-3-甲酸乙酯 7-Boc-5,6,7,8-四氢-1,2,4-三唑并[4,3-a]吡嗪 7-Boc-3-溴-5,6,7,8-四氢-1,2,4-三唑并[4,3-a]吡嗪 7-(叔丁氧基羰基)-5,6,7,8-四氢-[1,2,4]噻唑并[4,3-a]吡嗪-3-羧酸 6-溴-[1,2,4]噻唑并[1,5-a]吡嗪-2-胺 6-溴-[1,2,4]三唑并[1,5-a]吡嗪 6-溴-2-(呋喃-2-基)[1,2,4]噻唑并[1,5-a]吡嗪-8-胺 6-氯-2-甲基-[1,2,4]三唑并[1,5-A]吡嗪 6-氨基-[1,2,4]三唑并[1,5-a]吡嗪-8(7H)-酮 6,8-二溴-[1,2,4]噻唑并[1,5-a]吡嗪 6,8-二溴-2-甲基-[1,2,4]三唑并[1,5-A]吡嗪 5-溴-[1,2,4]噻唑并[1,5-a]吡嗪 5,8-二溴-[1,2,4]噻唑并[1,5-a]吡嗪 5,6,7,8-四氢-[1,2,4]三唑并[4,3-A]吡嗪盐酸盐 5,6,7,8-四氢-5-甲基-3-三氟甲基-1,2,4-噻唑并[4,3-a]吡嗪 5,6,7,8-四氢-5,8-二甲基-3-三氟甲基-1,2,4-噻唑并[4,3-a]吡啶 5,6,7,8-四氢-5,5-二甲基-3-(三氟甲基)-1,2,4-噻唑[4,3-A]吡嗪 5,6,7,8-四氢-3-甲氧基-1,2,4-噻唑并[4,3-a]吡嗪 5,6,7,8-四氢-1,2,4-三氮唑并[4,3-A]吡嗪-3-甲醇 5,6,7,8-四氢-1,2,4-三唑并[4,3-a]吡嗪盐酸盐 5,6,7,8-四氢-1,2,4-三唑并[4,3-a]吡嗪-3-甲酸乙酯 5,6,7,8-四氢-1,2,4-三唑并[4,3-A]吡嗪-3-羧酸乙酯盐酸盐 3-甲酰基-5,6-二氢-[1,2,4]三唑并[4,3-A]吡嗪-7(8H)-羧酸叔丁酯 3-甲氧基-5,6-二氢-[1,2,4]噻唑并[4,3-a]吡嗪-7(8h)-羧酸叔丁酯 3-甲基-5,6,7,8-四氢-[1,2,4]三唑并[4,3-A]吡嗪 3-环丙基-5,6,7,8-四氢-[1,2,4]三唑并[4,3-a]吡嗪 3-溴-5,6,7,8-四氢[1,2,4]噻唑并[4,3-a]吡嗪盐酸盐 3-溴-5,6,7,8-四氢-[1,2,4]三唑并[4,3-A]吡嗪盐酸盐 3-异丙基5,6,7,8-四氢[1,2,4]三唑[4,3-A]吡嗪 3-乙基-5,6,7,8-四氢-1,2,4-三唑并[4,3-a]吡嗪 3-三氟甲基-5,6,7,8-四氢-1,2,4-三唑并[4,3-a]吡嗪盐酸盐 3-(三氟甲基)-5,6-二氢-[1,2,4]噻唑[4,3-A]吡嗪-7(8H)-羧酸叔丁酯 3-(三氟甲基)-5,6,7,8-四氢-[1,2,4]三唑并[4,3-a]吡嗪 3-(4-氟苄基)-5,6,7,8-四氢-[1,2,4]三唑并[4,3-a]吡嗪 2-甲基-[1,2,4]噻唑并[1,5-a]吡嗪 2-环丙基-[1,2,4]噻唑并[1,5-a]吡嗪 2-(三氟甲基)-[1,2,4]噻唑并[1,5-A]吡嗪 2,5,8-三甲基[1,2,4]噻唑并[1,5-a]吡嗪 (2Z)-4-氧代-4-[3-(三氟甲基)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪-7-(8H)-基]-1-(2,4,5-三氟苯基)丁-2-酮 (2Z)-4-氧代-4-[3-(三氟甲基)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪-7(8H)-基]-1-(2,4,5-三氟苯基)丁-2-烯-2-胺 (2Z)-1-[5,6-二氢-3-(三氟甲基)-1,2,4-三唑并[4,3-a]吡嗪-7(8H)-基]-3-[[(1R)-1-苯乙基]氨基]-4-(2,4,5-三氟苯基)-2-丁烯-1-酮 (1,2,4)噻唑(1,5-a)吡嗪